Rising Tide Lifts US Biosimilars Market

The US biosimilars market is experiencing strong growth as regulations evolve and physician confidence in these products grows. But market patterns are changing.

• The introduction of biosimilars for the blockbuster drug Humira presented new market challenges, and meaningful adoption took nearly 18 months. However, companies learned valuable lessons with the introduction of this first pharmacy benefit biologic.
• Going forward, we expect that only a few biosimilars manufacturers will have attractive economics for each biologic molecule.
• To succeed, companies will need a very clear strategy for pipeline choices, internal development versus business development decisions, and go-to-market capabilities.